Hepatic artery chronomodulated infusion of irinotecan, 5-fluorouracil and oxaliplatin against liver metastases in heavily pretreated patients with colorectal cancer.

被引：0
|
作者：
Bouchahda, M
Tanaka, K
Adam, R
Giacchetti, S
Brézault-Bonnet, C
Gholam, D
Kunslinger, F
Castaing, D
Jasmin, C
Lévi, FA
机构：
[1] Hop Paul Brousse, Villejuif, France
[2] INSERM, E0354, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3722
引用
收藏
页码：299S / 299S
页数：1
相关论文
共 50 条
  • [21] HEPATIC ARTERIAL CHEMOTHERAPY WITH OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER
    Del Freo, A.
    Sanguinetti, F.
    Muttini, M. P.
    Pennucci, M. C.
    Mambrini, A.
    Manni, A.
    Della Seta, R.
    Lombardi, M.
    Spinelli, I.
    Torri, T.
    Cantore, M.
    ANNALS OF ONCOLOGY, 2004, 15 : 59 - 59
  • [22] Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients
    Santini, D
    Vincenzi, B
    La Cesa, A
    Caricato, M
    Schiavon, G
    Spalletta, B
    Di Seri, M
    Coppola, R
    Rocci, L
    Tonini, G
    ONCOLOGY, 2005, 69 (01) : 27 - 34
  • [23] Hepatic Arterial Infusion with Oxaliplatin, Irinotecan and Doxifluridine for Unresectable Liver Metastases of Colorectal Cancer
    Chen, Yi
    Yan, Zhiping
    Wang, Jianhua
    Wang, Xiaolin
    Luo, Jianjun
    Liu, Qingxin
    ANTICANCER RESEARCH, 2010, 30 (07) : 3045 - 3049
  • [24] Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases
    Neyns, B
    Van Nieuwenhove, Y
    Aerts, M
    Fontaine, C
    Vermeij, J
    Schallier, D
    Decoster, L
    De Mey, J
    Vandenbroucke, F
    Hoorens, A
    Delvaux, G
    De Gréve, J
    ANTICANCER RESEARCH, 2006, 26 (1B) : 611 - 619
  • [25] Relations between clinical outcomes and pharmacokinetics of irinotecan, oxaliplatin, and 5-fluorouracil during hepatic artery chronomodulated delivery of intravenous cetuximab in patients with extensive liver metastases from colorectal cancer: A translational study in European trial OPTILIV
    Levi, Francis
    KarabouA, Abdoulaye
    Etienne-Grimaldi, Marie-Christine
    Paintaud, Gilles
    Focan, C. N. J.
    Innominato, Pasquale F.
    Bouchanda, Mohamed
    Milano, Gerard
    Chatelut, Etienne
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma
    Martoni, A
    Mini, E
    Pinto, C
    Nobili, S
    Gentile, AL
    Dentico, P
    Angelelli, B
    Scicolone, S
    Piana, E
    Mazzei, T
    ANNALS OF ONCOLOGY, 2001, 12 (04) : 519 - 524
  • [27] Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer
    LaRocca, RV
    Glisson, SD
    Hargis, JB
    Kosfeld, RE
    Leaton, KE
    Hicks, RM
    Amin-Zimmerman, F
    SOUTHERN MEDICAL JOURNAL, 2004, 97 (09) : 831 - 835
  • [28] Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients
    Garufi, C
    Brienza, S
    Pugliese, P
    Aschelter, AM
    Bensmaine, MA
    Bertheault-Cvitkovic, F
    Nisticò, C
    Giunta, S
    Caterino, M
    Giannarelli, D
    Cosimelli, M
    Lévi, F
    Terzoli, E
    ANTI-CANCER DRUGS, 2000, 11 (06) : 495 - 501
  • [29] Hepatic resection of initially unresectable liver metastases from colorectal cancer after hepatic arterial infusion of oxaliplatin and systemic 5-fluorouracil and leucovorin
    Goere, D., Sr.
    Dsehais, I.
    de Baere, T.
    Boige, V.
    Malka, D.
    Bonnet, S.
    Dromain, C.
    Elias, D.
    Ducreux, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Dose intensity of oxaliplatin in 5-fluorouracil and leucovorin regimens in pretreated metastatic colorectal cancer.
    Jeong, KJ
    Oh, JM
    Choi, SK
    Oh, D
    PHARMACOTHERAPY, 2002, 22 (10): : 1356 - 1356
12345